Details for New Drug Application (NDA): 209302
✉ Email this page to a colleague
The generic ingredient in SILDENAFIL CITRATE is sildenafil citrate. There are twenty drug master file entries for this compound. Sixty-eight suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.
Summary for 209302
Tradename: | SILDENAFIL CITRATE |
Applicant: | Umedica |
Ingredient: | sildenafil citrate |
Patents: | 0 |
Pharmacology for NDA: 209302
Mechanism of Action | Phosphodiesterase 5 Inhibitors |
Medical Subject Heading (MeSH) Categories for 209302
Suppliers and Packaging for NDA: 209302
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
SILDENAFIL CITRATE | sildenafil citrate | TABLET;ORAL | 209302 | ANDA | A-S Medication Solutions | 50090-7181 | 50090-7181-0 | 10 TABLET in 1 BOTTLE (50090-7181-0) |
SILDENAFIL CITRATE | sildenafil citrate | TABLET;ORAL | 209302 | ANDA | REMEDYREPACK INC. | 70518-3969 | 70518-3969-0 | 30 TABLET in 1 BOTTLE, PLASTIC (70518-3969-0) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 50MG BASE | ||||
Approval Date: | Aug 25, 2020 | TE: | BX | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 100MG BASE | ||||
Approval Date: | Aug 25, 2020 | TE: | BX | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 25MG BASE | ||||
Approval Date: | Jun 15, 2021 | TE: | BX | RLD: | No |
Complete Access Available with Subscription